

Accepted Manuscript

Title: In vitro permeability of silver nanoparticles through porcine oromucosal membrane

Author: Marcella Mauro Matteo Crosera Carlotta Bianco
Francesca Bellomo Massimo Bovenzi Gianpiero Adami
Francesca LareseFilon



PII: S0927-7765(15)00280-5
DOI: <http://dx.doi.org/doi:10.1016/j.colsurfb.2015.04.061>
Reference: COLSUB 7066

To appear in: *Colloids and Surfaces B: Biointerfaces*

Received date: 23-1-2015
Revised date: 26-4-2015
Accepted date: 27-4-2015

Please cite this article as: M. Mauro, M. Crosera, C. Bianco, F. Bellomo, M. Bovenzi, G. Adami, F. LareseFilon, In vitro permeability of silver nanoparticles through porcine oromucosal membrane, *Colloids and Surfaces B: Biointerfaces* (2015), <http://dx.doi.org/10.1016/j.colsurfb.2015.04.061>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

HIGHLIGHTS

1
2
3
4
5
6
7
8
9
10
11
12
13

- Many devices are coated with silver NPs and come in contact with oral mucosa
- 19 nm AgNPs and only silver ions have been investigated through oral porcine mucosa
- Results showed similar flux permeation in both experiments
- It can be suggested that the permeation is mainly due to ions released from NPs
- AgNPs flux permeation through oral mucosa is higher compared to skin permeation

13

14

15 In vitro permeability of silver nanoparticles
16 through porcine oromucosal membrane

17

18

19 Marcella Mauro, MDPHD^a, Matteo Crosera, Post Doc^b, Carlotta Bianco, PhD^b,

20 Francesca Bellomo, PhD^a, Massimo Bovenzi, MD^a, Gianpiero Adami, PhD^b,

21 Francesca LareseFilon, MD^a

22

23 ^aClinical Unit of Occupational Medicine, Department of Medical Sciences, University of
24 Trieste, Via della Pietà 19, 1-34100 Trieste, Italy

25 ^b Department of Chemical and Pharmaceutical Sciences, University of Trieste, via
26 Giorgieri, 1- 34127 Trieste, Italy

27

28

29 Corresponding author: Tel +39 040 3992215; fax: +39 040 368199, e-mail adress: larese@units.it
30 (LareseFilon F.)

31

32

33 Word count for abstract: 151 words

34 Complete manuscript word count: body text (4041), figure legends (165), total: 4206

35 Number of figures/tables: 5 figures.

36 Funding: FRA2012 (Finanziamento Ricercatori di Ateneo) University of Trieste.

37

38 Declaration of interest: The authors report no current or previous conflicts of
39 interest.

40

41

42 Abstract

43 Silver nanoparticles (AgNPs) can come in contact with human oral mucosa due to
44 their wide use in food industry and hygiene devices. We evaluate transmucosal
45 absorption of 19 nm AgNPs using excised porcine buccal mucosa applied on Franz
46 diffusion cells. Two donor solutions were used: one containing AgNPs (0.5 g/L) and
47 one derived from the ultrafiltration of the former and containing only Ag in its
48 soluble form. Experiments were carried out separately for 4 hours. Silver flux
49 permeation was demonstrated through oral mucosa, showing similar values for
50 AgNPs ($6.8 \pm 4.5 \text{ ng cm}^{-2} \text{ h}^{-1}$) and Ag ions ($5.2 \pm 4.3 \text{ ng cm}^{-2} \text{ h}^{-1}$). Our study
51 demonstrates that silver can permeate the oromucosal barrier and that absorption
52 is substantially due to Ag ions, since no permeation difference was found using the
53 two solutions. Mucosal absorption has to be considered in further risk assessment
54 studies.

55

56 Keywords: Silver nanoparticles, mucosal membrane, in vitro, Franz cells,
57 permeation.

58

59

60

61

62

63

64

65

66

67

68

69

70 Background:

71

72 Silver nanoparticles (AgNPs) are diffusely used in food packaging, containers,
73 toothpaste and teeth brushes, nipples and nursing bottles, water purification
74 devices etc.^{1,2,3} These particles are therefore able to come in contact with oral
75 mucosa, whose penetration properties are not completely known. Silver is used for
76 its good antimicrobial properties and its safe profile,⁴ but in literature silver
77 intoxication (argyria) has been described through oral route, in people who drank it
78 for deliberate uptake,^{5, 6} or through skin route, when wound dressings containing
79 Silver NPs are used on burns for more than 30% of the skin surface.⁷ The Agency
80 for Toxic Substances and Disease Registry (ATSDR) describes argyria as a "cosmetic
81 problem", since it consist mostly in a not reversible bluish-gray discoloration of the
82 skin.⁸ Nevertheless there are isolated reports of more serious neurologic, renal and
83 hepatic complications caused by the ingestion of colloidal silver.^{9, 10}

84 Oral mucosa traditionally acts as first barrier to xenobiotics in the digestive tract,
85 but it is also a possible drug delivery route for medical formulations,¹¹ since it can
86 avoid liver metabolism if compared to the traditional intestinal route.¹²

87 Due to its histological structure oral mucosa shows a permeability 20 times higher
88 to water¹³ and 4 up to 4.000 times higher to different drugs compared to skin,¹⁴ but
89 very little is known about its behavior towards NPs penetration. It has been
90 demonstrated that the main penetration barrier for drugs is the top third region of
91 the epithelium, because the cells size grows, and the cells shape becomes flatter
92 from the basal to the superficial layers.¹⁵

93 Since the spread of nanotechnologies has taken place in many fields of everyday
94 life, there are many available products containing AgNPs but the knowledge on NPs
95 permeation properties through mucosal membranes is still lacking.¹⁶ Some authors
96 demonstrated the capability of mucus layer to embed polystyrene NPs,¹⁷ others
97 demonstrated that them can cross this barrier and penetrate the buccal mucosa in
98 a size dependent manner.¹⁸ Nanosized pathogens too (Norwalk virus, 38 nm

99 diameter, and HPV, 55 nm diameter) can easily diffuse through the mucus layer that
100 protect the gastric and nasal mucosa.^{18, 19} On this basis mucosal vaccines have
101 been developed in recent years and some of them are delivered through oral
102 mucosa (as the vaccines against cholera, rotavirus and typhoid fever) while others
103 through nasal mucosa by spray.^{20, 21, 22} There is evidence that the administration of
104 antigens at mucosal portals of entry inside lipid nanocapsules can induce a T-
105 cellular immune responses up to 13-fold higher rather than the equivalent soluble
106 formulation.²³

107 Since NPs penetration through oral mucosa is not fully known, we performed
108 experiments to investigate AgNPs permeation. We chose to test AgNPs due to their
109 common use as antimicrobial agents in many devices that come in contact with oral
110 cavity. We used porcine lining mucosa because it is the most similar to the human
111 one¹³ and is the oral region which is expected to contribute most to oromucosal
112 absorption. In this study, experiments were performed using the Franz cell method,
113 adapting the experience and the protocols employed during the European project
114 EDETOX (Evaluations and predictions of Dermal absorption of TOXic chemicals)²⁴, a
115 three-year research program (2001-2004) funded by European Union (EDETOX,
116 2000) and already used to testing skin permeation of other metal nanoparticles
117 such as silver, gold and cobalt.^{25, 26, 27}

118

119

120 Materials and methods

121

1221 Chemicals:

123 All chemicals used were of analytical grade. Sodium chloride, sodium hydrogen
124 phosphate, potassium dihydrogen phosphate, glutaraldehyde (50% v/v), nitric acid
125 (69% v/v), hydrochloric acid (36.5-38% v/v) were purchased from Sigma Aldrich
126 (Milan, Italy), ammonium hydroxide (25%) from J.T. Baker (Milan Italy). Water
127 reagent grade was produced with a Millipore purification pack system (milliQ
128 water).

129 The physiological solution used as receptor fluid was prepared by dissolving 2.38 g
130 of Na_2HPO_4 , 0.19 g of KH_2PO_4 and 9 g of NaCl into 1 L of milliQ water (final pH =
131 7.35)

132

133.2 Silver nanoparticles characterization

134 2.2.1 Donor phases preparation

135 AgNPs, stabilized with polyvinylpyrrolidone (content of silver: 25% w/w, polymer
136 75%), were supplied by NanoAmor Materials Inc, (Houston, Texas, U.S.A.).

137 In order to better distinguish the permeation between AgNPs and silver ions,
138 released from the NPs, two different donor phases were prepared just before the
139 experiments.

140 The first donor phase, consisting of the AgNPs solution, was prepared using 200
141 mg (ratio metal:polymer=1:4) of AgNPs dispersed by sonication in 100 ml of
142 physiological solution to obtain a concentration of 0.50 g/L (as metal content).

143 The nanoparticles suspension in water had a presence of 5% of silver in ionized
144 form, determined using the ultrafiltration technique. The silver ions presence did
145 not significantly change in four hours.

146 The second donor phase was prepared by the ultrafiltration of the first one to obtain
147 only the water-soluble silver species present in the first donor phase at the moment
148 of the experiment. Four ml of the AgNPs solution were ultrafiltered in centrifuge at
149 5000 rpm for 30 min by means of Amicon Ultra-4 centrifugal filters (10 KDa MWCO)
150 in order to separate the AgNPs from the aqueous solution. The filtration has been

151 repeated on five different aliquots in order to obtain an adequate solution volume to
152 perform silver quantification analysis and permeation experiments. The five filtered
153 aliquots were mixed for a total of 20 ml and used during the permeation
154 experiments.

155 2.2.2 Ion release from AgNPs

156 In order to define the percentage of silver ions inside the AgNPs solution, the donor
157 phases have been analyzed by means of Inductively Coupled Plasma –Atomic
158 Emission Spectroscopy (ICP-AES).

159 2.2.3 Transmission electron microscope characterization

160 AgNPs dispersed in physiological solution were characterized to obtain nanoparticles
161 size and morphology on a transmission electron microscope (EM208; Philips,
162 Eindhoven, The Netherlands operating at 200 kV) with an high definition acquisition
163 system based on a side-mounted TEM camera OSIS Morada and a iTEM software
164 platform (Olympus Soft Imaging Solutions GmbH, Münster, Germany).

165

166 2.2.4 Dynamic light scattering measurements

167 The average values of the AgNPs size and polydispersity, defined as a relative width
168 of the size distribution, were determined from dynamic light scattering (DLS)
169 measurements, using a Zetasizer Nano Z (Malvern Instruments Ltd) analyzer
170 applying a 633 nm laser oriented at 173° relative to the sample.

171 The software was optimized to report summary statistics based upon the intensity
172 of light scattered. Four hundred μ l sample volumes from nanosilver dispersion
173 (dilution 1:5 in physiological solution) were loaded into low size disposable cuvette
174 (supplied by manufacturer) and summary statistics were obtained using
175 quadruplicate 3 min analysis (total analysis time=12min). Instrument performance
176 was verified using a polymer reference standard known to be 60 nm.

177 2.2.5 Zeta potential measurement

178 Measurements were carried out using a ZetasizerNano ZS (Malvern). An aqueous
179 suspension of silver nanoparticles was diluted 1:5 in a physiological solution. The
180 zeta potential was calculated using Henry's equation.

181

182.3 Preparation of mucosal membranes

183 Due to its morphological and enzymatic similarities with the human mucosa¹³
184 porcine oral mucosa was used for the in vitro experiments. The membranes were
185 obtained immediately after pig's slaughter (age 1 year). During the transport to
186 laboratory the tissue was stored at 4°C and then in freezer at -80°C for a period of
187 time up to, but not exceeding, 1 week. On the day of the experiment, the tissue
188 was removed from the freezer and thawed in physiological solution, at room
189 temperature, for approximately 30 min before the permeation experiment. It has
190 been shown that this method of storage does not affect the mucous barrier
191 properties, since no change in the permeability has been described.²⁸The underlying
192 connective tissue was manually removed with a scalpel blade, and uniform
193 thickness of approximately 0,6 mm was achieved with surgical scissors. Mucous
194 membranes integrity was tested as suggested by Lestari.²⁹

195

196 In vitro diffusion system

197 Mucosal permeation studies were performed using static Franz diffusion cells. The
198 receiver compartments have a mean volume of 14.0 mL and were maintained at
199 37°C by means of circulation of thermostated water in the jacket surrounding the
200 cells throughout the experiment. This temperature value has been chosen in order
201 to reproduce physiological conditions. The concentration of the salt in the receiver
202 fluids was approximately the same that can be found in the blood. The solution in
203 each cell was continuously stirred using a Teflon coated magnetic stirrer.

204 Each excised sheet of mucosa was clamped between the donor and the receptor
205 compartment in such a way that the epithelium faced the donor, and the connective
206 tissue region faced the receiver compartment; the mean exposed area of the
207 mucous membranes was 3.29 cm².

208

209 The experiments were performed as follows:

210 Exp. 1: At time 0, the exposure chambers of 4 Franz diffusion cells were filled with
211 1 mL of physiological solution and 0.5 mL of AgNPs suspension (75 µg cm⁻²), in
212 order to provide an infinite dose: the concentration in each cell has been confirmed
213 at the end of the experiments by means of ICP-AES analysis.

214 At selected intervals (30, 60, 90, 120, 150, 180, 210, 240 min) 1 mL of the
215 receiving bathing solution was removed and collected for the analysis, and
216 immediately replaced with an equal volume of fresh made physiological solution. In
217 order to avoid the precipitation of silver chloride (AgCl), 100 µl of NH₄OH 1N was
218 added to each sample collected.

219 The experiment was carried out for 4 hours, as suggested in other studies.¹⁶At the
220 end of the experiment the mucosa pieces were removed, washed abundantly with
221 milliQ water, and subsequently stored in the freezer together with mucosal bathing
222 solutions and the donor solutions for the following analysis

223 The experiment was repeated twice for a total of 8 cells.

224 Exp. 2: the exposure chambers of 4 Franz diffusion cells were filled with 1 mL of
225 physiological solution and 0.5 mL of the Ag ultrafiltered solution. The other test
226 conditions were the same of the experiment 1. The experiment was repeated twice
227 for a total of 8 cells.

228 Blanks: for each experiment, two cells were added as blank. The blank cells were
229 treated as the other cells with the exception that the exposure chambers were filled
230 only with physiological solution.

2315 Mucosa digestion after the experiment

232 All the mucosal exposed samples were collected and stored individually in freezer at
233 -25°C for the following digestion and analysis. At the time of the analyzes, the skin
234 membranes were dried for 2 hours at room temperature, weight, and then cut into
235 sections and put into glass tubes with 10 mL of HNO_3 69% v/v for digestion. The
236 obtained solutions were heated at 80°C for 8 hours and then diluted to a final
237 volume of 10 ml with milliQ water for the ICP-AES analysis.

238

239 Quantitative analysis

240 An Inductive Coupled Plasma Mass Spectrometer (ICP-MS 7500 CE Agilent
241 instrument with integrated autosampler) was used to determinate the total silver
242 concentration in the receiver phases.

243 A seven-point standard curve was used for ICP-MS measurements (0.01, 0.05, 0.1,
244 0.5, 1, 5 and 10 $\mu\text{g/L}$, ion mass 107 u.m.a.). The limit of detection of silver was
245 0.005 $\mu\text{g/L}$ for ICP-MS and the precision of the measurements expressed as
246 repeatability (RSD %) was always lower than 5%.

247 The total silver concentration in the donor phases and in the solutions resulting
248 from the skin sample mineralization were performed by Inductively Coupled
249 Plasma-Atomic Emission Spectrometry (ICP-AES) using a Spectroflame Modula E
250 optical plasma interface (OPI) instrument (by SPECTRO, Germany). The analysis
251 were conducted using a calibration curve obtained by dilution (range: 0–10 mg/L)
252 of Silver ICP standard solution for ICP-AES analysis (Sigma-Aldrich, Italy). The limit
253 of detection (LOD) at the operative wavelength of 328.068 was 0.010 mg/L. The
254 precision of the measurements expressed as repeatability (RSD %) was always
255 lower than 5%.

256 All standard solutions used for calibration curves had been prepared using
257 physiological solution and 10% of ammonium hydroxide 1N in order to reproduce
258 the matrix of the samples.

259

260 SEM-EDX analysis

261 One mucosal sample for each experiment (one blank, one exposed to AgNPs and
262 one to ultrafiltered soluble silver) was fixed with glutaraldehyde 10% v/v, washed
263 with ethanol-water at increasing concentration of ethanol and stored in ethanol
264 98% until SEM analysis.

265 Analysis were performed by means of a Scanning Electron Microscope (Hitachi, TM
266 3000) equipped with Energy Dispersive X-ray Spectroscopy (EDX SwiftEd 3000)
267 with a magnification of 30000x and an accelerating voltage of 15 kV. With this
268 setting silver clusters with a diameter above 50 nm were easily detected.

269

270 2.8 Data analysis

271 Data analysis was performed with Excel for Windows, release 2007 and Stata
272 Software, version 11.0 (StataCorp LP, College Station, TX, USA). All data were
273 reported as mean or median as measures of central tendency and standard
274 deviation (SD) or quartiles as measure of dispersion. The difference among
275 independent data was assessed by means of the Mann-Whitney test. A p value of
276 <0.05 was considered as the limit of statistical significance.

277

278

279

280

281 3. Results:

282 3.1 characterization of AgNPs colloidal dispersion

283 The colloidal dispersion of AgNPs in water showed Plasmon absorption at 405 nm.
284 Transmission Electron Microscopy (TEM) measurements revealed that AgNPs used in
285 donor solution were quite uniform in size and shape and as small as 19 ± 5 nm
286 (number of measured nanoparticles: 100). At the concentration used in the
287 permeation experiments no aggregates have been visualized (fig. 1).

288 The quantitative analysis of the filtered aliquots revealed that 5% of the donor
289 solution was ionized and a dose of $3.8 \mu\text{g cm}^{-2}$ of silver was applied as donor phase
290 in exp 2. Size distributions obtained by DLS are quite narrow, as presented in figure
291 2. The analysis revealed a z-average size (d.nm) equal to 57.1 and a polydispersity
292 index (PdI) of 0.28 (fig. 2), while Zeta potential was equal to -11.4 ± 0.2 mV.

293 The apparent mismatch between TEM and DLS sizes is the result of various facts,
294 as elsewhere reported³⁰. Firstly, the laser scattering technique measures the
295 hydrodynamic diameter inclusive of PVP and coordinated molecules. Furthermore,
296 polymer-protected metal NPs can form agglomerates consisting of various metal
297 cores wrapped up in the same polymer chain. The mean hydrodynamic diameters of
298 these agglomerates, revealed by DLS, are therefore larger than the mean sizes of
299 the primary NPs, revealed by TEM.

300

301 3.2 Ag permeation through mucous membrane

302 Passive silver flux permeation was demonstrated through oral mucosa. Figure 3
303 shows the time-dependent increasing trend of metal concentrations in receiving
304 phases. The final values, expressed as mean and standard deviation, were $12.2 \pm$
305 $7.4 \mu\text{g/cm}^2$ and $11.8 \pm 11.1 \mu\text{g/cm}^2$ in cells exposed to AgNPs and to Ag ions
306 (ultrafiltered solution), respectively. Flux permeation after 4 hours of application
307 showed similar final values ($6.8 \pm 4.5 \text{ ng cm}^{-2} \text{ h}^{-1}$ and $5.2 \pm 4.3 \text{ ng cm}^{-2} \text{ h}^{-1}$) and
308 lag times (1.9 ± 0.7 h and 1.7 ± 0.7 h) using AgNPs and ultrafiltered solution,
309 respectively (mean and standard deviation).

310 Silver content inside the mucosa showed similar values in both experiments too
311 (median $0.8 \mu\text{g}/\text{cm}^2$ and $1.4 \mu\text{g}/\text{cm}^2$, 25th Pct 0.5 and 0.9, 75th Pct 0.1 and 0.2, in
312 membranes exposed to AgNPs and to Ag ions (ultrafiltered solution), respectively)
313 as showed in fig.4.

314 SEM-EDX investigations showed no traces of AgNPs clusters in the tissue. SEM
315 analysis revealed the presence of electrondense zones upon the mucosal tissue
316 exposed to Ag-NPs, but microanalysis on that points showed the absence of silver
317 or silver chloride particles (fig. 5A-F).

318

319. Discussion

320 The oral mucosa is an attractive biological membrane, since it owns a dual role in
321 the body: on one side it acts as the first barrier towards xenobiotics and human
322 pathogens, and on the other it acts as the first gateway to systemic circulation
323 towards substances which can permeate it. Many drugs have been studied in order
324 to be absorbed through sublingual administration, but very few is known about
325 permeation properties towards nanoparticles.

326 Previous studies have shown that the oral mucosa permeability depends mainly on
327 the type of epithelium, the type and amount of intercellular lipids and the chemical
328 nature of the substances applied. Regions coated with nonkeratinized epithelium,
329 such as buccal mucosa and floor of mouth (lining mucosa), which we used in the
330 study, contain glycosylceramides, and have a significantly higher permeability
331 compared to regions with keratinized epithelium, such as hard palate and gengiva,
332 which contain predominantly neutral lipids.³¹

333 The first filter to external substances is the mucous layer³² (average thickness of
334 $70\text{-}100 \mu\text{m}$), which consists mostly of a high molecular weight mucin, called MG1,
335 which is a component of the saliva that binds to the surface of the buccal
336 epithelium.^{33, 34} However it has been demonstrated that the main penetration
337 barrier for drugs is the top third region of the epithelium, due to the growing size
338 and shape of the cells that go up from the basal to the superficial layers.¹⁵

339 The xenobiotics that can cross the hindrance of this barrier reach the underneath
340 connective tissue, called "lamina propria", which provides support and nourishment
341 to the mucosa through a network of blood vessels, capillaries and smooth

342 muscles,¹¹ and from here substances can spread throughout the body via systemic
343 circulation.

344 AgNPs can come in contact with human mucosa because are present in many
345 products such as toothpaste, alcohol free mouthwash³⁵, nasal sprays, endotracheal
346 tubes^{36,37} and urinary catheters,^{38,39} to prevent infections. Since the antimicrobial
347 effect of silver depends on superficial contact, the high surface area to volume ratio
348 offered by NPs allows a broader interaction with bacterial membrane and a wider
349 contact with microorganisms.

350 Few studies have been conducted to investigate AgNPs behavior towards the
351 mucosa of the digestive tract. Shahare and colleagues⁴⁰ showed that after an oral
352 administration of 3-20 nm AgNPs to albino mice for 3 weeks, at a dose of 5, 10, 15
353 and 20 mg/kg body weight, all groups treated had a significant decrease in the
354 body weight, confirming a toxic effect of the metal. Histological changes of the
355 mucosa have been reported, such as a damage of the epithelial cell micovilli and
356 the intestinal glands, which the authors hypothesized as the reason for the
357 absorptive capacity reduction of intestinal epithelium and hence for the weight loss.
358 Walczak and colleagues⁴¹ investigated the behavior of 60 nm AgNPs and of AgNO₃
359 ions in an in vitro human digestion model. They found that after gastric digestion
360 and in presence of proteins, the number of particles dropped significantly, due to
361 the formation of clusters, and subsequently disintegrated back to single 60 nm
362 AgNPs during intestinal digestion. Therefore results showed that under physiological
363 conditions AgNPs can reach the intestinal wall in their initial size.

364 No other studies investigated AgNPs mucosal absorption but 2 studies
365 demonstrated that polystyrene Nps can cross the pig mucosa: Holpuch and
366 coworkers⁴² showed that 210 nm polystyrene NPs can cross intact human
367 epithelium, derived from oral explants, and can be found in the underlying
368 connective tissue. Teubl and colleagues¹⁸ investigated more systematically NPs
369 behavior through oral mucous membrane, by performing experiments with different
370 size and superficial charge of the NPs, and at different mucosal temperatures. They
371 demonstrated that neutral 25 nm, 50 nm and 200 nm polystyrene nanoparticles
372 (PP) can all cross the mucus layer and penetrate the buccal mucosa in a size
373 dependent manner, surprisingly higher for those with bigger size. This is in contrast
374 to the generally accepted assumption that decreasing the particle diameter
375 increases the absorption^{43, 44}.

376 Our study investigated for the first time the behavior of silver NPs and its
377 ultrafiltered solution towards oral mucosa, using 19 nm AgNPs applied in vitro on
378 porcine oral explants. The aim was to distinguish the percentage of permeation, if
379 any, due to NPs themselves from the percentage due to the ions issued. The
380 findings suggest that an absorption through passive diffusion takes place, and it is
381 mainly due to silver ions. This result is consistent with the ones obtained by other
382 authors,⁴⁵ whom demonstrated that the dose-dependent toxic effects of AgNPs on
383 animals (death, weight loss, cardiac enlargement, altered liver enzymes levels and

384 immunological effects) were substantially mediated by silver ions released from
385 AgNPs. Gaillet and coworkers support the same theory in a recent review.⁴⁶

386 Indeed Silver, in whatever form, is not an essential mineral for humans, and so it
387 can exert toxic effects. Systemic intoxication, called "argyria", is fortunately a rare
388 event, but a more common effect in human is the uptake reduction of some drugs,
389 such as thyroxine, penicillamine and of some antibiotics,⁴⁷.

390 For this reason the governmental agency Food and Drug Administration (FDA)
391 issued numerous warning letters to e-commerce sites which promoted colloidal
392 silver as antibiotic or drug for medical purposes.^{48, 49, 50}

393 It could be interesting compare our results with those obtained by Bianco and
394 coworkers,⁵¹ where AgNPs have been applied on full thickness human skin in similar
395 experimental conditions. Interestingly the flux through oral mucosa is about 1 order
396 of magnitude higher compared to skin, and the time required to reach a constant
397 flux trough the membrane is definitely lower through the mucosa. This higher
398 permeability is attributable to a slightly different histological structure of the
399 mucosa compared to skin.

400 Our study adds important information to understand how nanoparticles can enter
401 the body but nevertheless the protocol used presented some limitations related to:
402 1) the in-vitro condition, which can underestimate real world scenarios, since only
403 passive diffusion can be studied using Franz-cells and 2) the use of porcine mucosa,
404 which is a good model to study human's mucosa but there are no data, yet, which
405 allow to bridge interspecies results.

406

407

408. Conclusions

409 Our study investigated the permeation of 19 nm silver nanoparticles (AgNPs) across
410 excised porcine oral lining mucosa, using an in vitro diffusion cell system.

411 We demonstrated for the first time that AgNPs, can lead to silver absorption
412 through oral mucosa, in a similar amount when AgNPs or silver soluble form is
413 used, suggesting that the permeation of the mucosa is related mainly to ions
414 diffusion. A further support to this hypothesis comes from the SEM-EDX results,
415 since no evidence of AgNPs clusters has been revealed, while the quantification of
416 total silver on the mineralized tissue ensures the presence of the metal.

417 Moreover the comparison with flux permeation values through the skin barrier,
418 when similar experimental conditions were used, suggest that the permeability of
419 silver through oral mucosa is one order of magnitude greater compared to skin,
420 leading to a higher uptake in in-vivo conditions.

421 Even if the amount of silver found should be not hazardous for human health, these
422 data suggest that oral cavity should be part of further risk assessment studies,
423 since it acts as the first barrier for systemic uptake and can come in contact with
424 different types of nanoparticles. Moreover this study investigated only the intact
425 mucosa, but in everyday life there are common circumstances which may damage
426 the mucosal integrity, such as gastroesophageal reflux, infections or accidental
427 abrasions, which all can lead to an increase in the oromucosal uptake.

428

429

430

431

432 References:

433 1. Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH, Chang HK, Lee JH,
434 Oh KH, Kelman BJ, Hwang IK, Yu IJ. Subchronic oral toxicity of silver
435 nanoparticles. Part Fibre Toxicol.2010; 6;7:20. doi: 10.1186/1743-8977-7-20.

436 2. Hadrup N, Loeschner K, Bergström A, Wilcks A, Gao X, Vogel U, Frandsen HL,
437 Larsen EH, Lam HR, Mortensen A. Subacute oral toxicity investigation of
438 nanoparticulate and ionic silver in rats.2012; Arch Toxicol. 2012; 86 (4):543-
439 51.

- 440 3. Collart D, Mehrabi S, Robinson L, Kepner B, Mintz EA. Efficacy of
441 oligodynamic metals in the control of bacteria growth in humidifier water tanks
442 and mist droplets. *J Water Health*. 2006; 4(2):149-56.
- 443 4. Bouwmeester H, Dekkers S, Noordam MY, Hagens WI, Bulder AS, de Heer C,
444 ten Voorde SE, Wijnhoven SW, Marvin HJ, Sips AJ. Review of health safety
445 aspects of nanotechnologies in food production. *RegulToxicolPharmacol*. 2009;
446 53(1):52-62.
- 447 5. Chang AL, Khosravi V, Egbert B. A case of argyria after colloidal silver
448 ingestion. *J CutanPathol*. 2006; 33(12):809-11.
- 449 6. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A
450 review of the in vivo and in vitro toxicity of silver and gold particulates: particle
451 attributes and biological mechanisms responsible for the observed toxicity. *Crit*
452 *Rev Toxicol*. 2010; 40(4): 328-46
- 453 7. Trop M, Novak M, Rodl S, Hellbom B, Kroell W, Goessler W. Silver-coated
454 dressing acticoat caused raised liver enzymes and argyria-like symptoms in
455 burn patient. *J Trauma*. 2006; 60(3):648-52
- 456 8. "ToxFAQs™ for Silver". Agency for Toxic Substances and Disease Registry.
457 Retrieved January 2013.
- 458 9. Brandt D, Park B, Hoang M, Jacobe HT. Argyria secondary to ingestion of
459 homemade silver solution. *J Am AcadDermatol*. 2005;53 (2 Suppl 1):S105-7.
- 460 10. Stepien KM, Morris R, Brown S, Taylor A, Morgan L. Unintentional silver
461 intoxication following self-medication: an unusual case of corticobasal
462 degeneration. *Ann ClinBiochem*. 2009;46 (Pt 6):520-2

- 463 11. Harris D, Robinson JR. Drug delivery via the mucous membranes of the
464 oral cavity. *J Pharm Sci.* 1992; 81(1):1-10.
- 465 12. Wertz PW, Squier CA. Cellular and molecular basis of barrier function in
466 oral epithelium. *Crit Rev Ther Drug Carrier Syst.* 1991; 8 (3):237-69. Review.
- 467 13. Lesch CA, Squier CA, Cruchley A, Williams DM, Speight P. The
468 permeability of human oral mucosa and skin to water. *J Dent Res.* 1989;
469 68(9):1345-9.
- 470 14. Fox CL Jr, Modak SM. Mechanism of silver sulfadiazine action on burn
471 wound infections. *Antimicrob Agents Chemother.* 1974; 5(6):582-8.
- 472 15. Gandhi, R.E. and Robinson, J.R., Bioadhesion in drug delivery, *Ind. J.*
473 *Pharm. Sci.* 1988; 50:145-152.
- 474 16. Roblegg E, Fröhlich E, Meindl C, Teubl B, Zaversky M, Zimmer A.
475 Evaluation of a physiological in vitro system to study the transport of
476 nanoparticles through the buccal mucosa. *Nanotoxicology.* 2012; 6(4):399-413.
- 477 17. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA.
478 Diffusion of macromolecules and virus-like particles in human cervical mucus.
479 *Biophys J.* 2001; 81(4):1930-7.
- 480 18. Teubl BJ, Meindl C, Eitzlmayr A, Zimmer A, Fröhlich E, Roblegg E. In-
481 vitro permeability of neutral polystyrene particles via buccal mucosa. *Small.*
482 2013; 9 (3):457-66.
- 483 19. Lai SK, Wang YY, Hida K, Cone R, Hanes J. Nanoparticles reveal that
484 human cervicovaginal mucus is riddled with pores larger than viruses.
485 *ProcNatlAcadSci U S A.* 2010; 107(2):598-603.

- 486 20. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.
487 Intranasal administration of a proteosome-influenza vaccine is well-tolerated
488 and induces serum and nasal secretion influenza antibodies in healthy human
489 subjects. *Vaccine*. 2006; 24(3):254-62.
- 490 21. Smith JH, Brooks P, Johnson S, Tompkins SM, Custer KM, Haas DL,
491 Mair R, Papania M, Tripp RA. Aerosol vaccination induces robust protective
492 immunity to homologous and heterologous influenza infection in mice. *Vaccine*.
493 2011; 29(14):2568-75.
- 494 22. Smith JH, Papania M, Knaus D, Brooks P, Haas DL, Mair R, Barry J,
495 Tompkins SM, Tripp RA. Nebulized live-attenuated influenza vaccine provides
496 protection in ferrets at a reduced dose. *Vaccine*. 2012; 30(19): 3026-33
- 497 23. Li AV, Moon JJ, Abraham W, Suh H, Elkhader J, Seidman MA, Yen M, Im
498 EJ, Foley MH, Barouch DH, Irvine DJ. Generation of effector memory T cell-
499 based mucosal and systemic immunity with pulmonary nanoparticle vaccination.
500 *SciTransl Med*. 2013; 5(204) 204ra130
- 501 24. Edetox, 2000. Evaluations and Predictions of Dermal Absorption of
502 Toxic Chemicals, EU Framework V: Quality of Life, Environment and Health Key
503 Action Funding. (Project Number: QLKA-2000-00196).
- 504 25. Larese FF, D'Agostin F, Crosera M, Adami G, Renzi N, Bovenzi M, Maina
505 G. Human skin penetration of silver nanoparticles through intact and damaged
506 skin. *Toxicology*. 2009; 255(1-2):33-7
- 507 26. Filon FL, Crosera M, Adami G, Bovenzi M, Rossi F, Maina G. Human skin
508 penetration of gold nanoparticles through intact and damaged skin.
509 *Nanotoxicology*. 2011; 5(4):493-501.

- 510 27. LareseFilon F1, Crosera M, Timeus E, Adami G, Bovenzi M, Ponti J,
511 Maina G. Human skin penetration of cobalt nanoparticles through intact and
512 damaged skin. *Toxicol In Vitro*. 2013; 27(1):121-7.
- 513 28. Nicolazzo JA, Reed BL, Finnin BC. The effect of Various In Vitro
514 Conditions on the Permeability Characteristics of the Buccal Mucosa. *Journal of*
515 *Pharmaceutical Sciences* 2003; 92 (12): 2399-2410
- 516 29. Lestari ML, Nicolazzo JA, Finnin BC. A novel flow through diffusion cell
517 for assessing drug transport across the buccal mucosa in vitro. *J Pharm Sci*.
518 2009; 98(12):4577-88.
- 519 30. Blosi M, Albonetti S, Dondi M, Martelli C, Baldi G.vMicrowave-
520 assistedpolyolsynthesis of Cu nanoparticles. *J.Nanopart. Res.* 2011; 13:127-
521 138
- 522 31. Squier CA, Wertz PW, Cox P. Thin-layer chromatographic analyses of
523 lipids in different layers of porcine epidermis and oral epithelium. *Arch Oral Biol*.
524 1991; 36(9):647-53.
- 525 32. Huh CH, Bhutani MS, Farfán EB, Bolch WE. Individual variations in
526 mucosa and total wall thickness in the stomach and rectum assessed via
527 endoscopic ultrasound. *Physiol Meas*. 2003; 24(4):N15-22.
- 528 33. Bykov VL. [The tissue and cell defense mechanisms of the oral
529 mucosa]. *Morfologiiia*. 1996; 110(6):14-24.
- 530 34. Bykov VL. [The functional morphology of the epithelial barrier of the
531 oral mucosa]. *Stomatologiiia (Mosk)*. 1997; 76 (3):12-7. Review.

- 532 35. Abadi MF, Mehrabian S, Asghari B, Namvar AE, Ezzatifar F, Lari AR.
533 Silver nanoparticles as active ingredient used for alcohol-free mouthwash. *GMS*
534 *Hyg Infect Control*. 2013; 8(1): Doc05. doi: 10.3205/dgkh000205.
- 535 36. Bouadma L, Wolff M, Lucet JC. Ventilator-associated pneumonia and its
536 prevention. *Curr Opin Infect Dis*. 2012;25 (4):395-404.
- 537 37. Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD,
538 Craven DE, Roberts PR, Arroliga AC, Hubmayr RD, Restrepo MI, Auger WR,
539 Schinner R; NASCENT Investigation Group. Silver-coated endotracheal tubes and
540 incidence of ventilator-associated pneumonia: the NASCENT randomized
541 trial. *JAMA*. 2008;300 (7):805-13.
- 542 38. Agarwala M, Barman T, Gogoi D, Choudhury B, Pal AR, Yadav RN. Highly
543 effective antibiofilm coating of silver-polymer nanocomposite on polymeric
544 medical devices deposited by one step plasma process. *J Biomed Mater Res B*
545 *Appl Biomater*. 2014;102 (6):1223-35.
- 546 39. Chakravarti A, Gangodawila S, Long MJ, Morris NS, Blacklock AR,
547 Stickler DJ. An electrified catheter to resist encrustation by *Proteus mirabilis*
548 biofilm. *J Urol*. 2005;174(3):1129-32.
- 549 40. Shahare B, Yashpal M. Toxic effects of repeated oral exposure of silver
550 nanoparticles on small intestine mucosa of mice. *Toxicol Mech Methods*.
551 2013;23(3):161-7
- 552 41. Walczak AP¹, Fokkink R, Peters R, Tromp P, Herrera Rivera ZE, Rietjens
553 IM, Hendriksen PJ, Bouwmeester H. Behaviour of silver nanoparticles and silver
554 ions in an in vitro human gastrointestinal digestion model. *Nanotoxicology*.
555 2013;7(7):1198-210

- 556 42. Holpuch AS, Hummel GJ, Tong M, Seghi GA, Pei P, Ma P, Mumper RJ,
557 Mallery SR. Nanoparticles for local drug delivery to the oral mucosa: proof of
558 principle studies. *Pharm Res.* 2010; 27(7):1224-36.
- 559 43. Hillyer JF, Albrecht RM J. Gastrointestinal persorption and tissue
560 distribution of differently sized colloidal gold nanoparticles. *Pharm Sci.*
561 2001;90(12):1927-36.
- 562 44. Florence AT. Nanoparticle uptake by the oral route: Fulfilling its
563 potential? *Drug Discov Today Technol.* 2005;2(1):75-81.
- 564 45. Hadrup N, Lam HR. Oral toxicity of silver ions, silver nanoparticles and
565 colloidal silver-a review. *RegulToxicolPharmacol.* 2014; 68(1):1-7.
- 566 46. Gaillet S, Rouanet JM. Silver nanoparticles: Their potential toxic effects
567 after oral exposure and underlying mechanisms - A review.*Food*
568 *ChemToxicol.* 2014 Dec 30. pii: S0278-6915(14)00530-4. doi:
569 10.1016/j.fct.2014.12.019.
- 570 47. Pamela L. Drake, M.P.H., National Institute for Occupational Health and
571 Safety; Edmund Pribitkin, M.D., Thomas Jefferson University; and Wendy
572 Weber, N.D., Ph.D., M.P.H., NCCAM (July 2009). Colloidal Silver Products. U.S.
573 Department of Health and Human Services.
- 574 48. "Colloidal Silver Not Approved". U.S. Food and Drug Administration.
575 2007-02-12. Retrieved 2008-09-22.
- 576 49. "FDA Warning Letter". U.S. Food and Drug Administration. 2001-03-13.
577 Retrieved 2008-09-22.
- 578 50. "FDA Warning Letter". U.S. Food and Drug Administration. 2011.
579 Retrieved 2013-04-11.

580 51. Bianco C, Adami G, Crosera M, Larese F, Casarin S, Castagnoli C, Stella
581 M, Maina G. Silver percutaneous absorption after exposure to silver
582 nanoparticles: a comparison study of three human skin graft samples used for
583 clinical applications. Burns. 2014;40 (7):1390-6.

584

585

FIGURE LEGENDS

586 Fig.1. TEM images of the AgNPs dispersed in physiological solution: NPs appeared
587 uniform in size and shape and as small as 19 ± 5 nm (A: bar=200nm; B:
588 bar=100nm).

589

590 Fig.2. DLS analysis. The curve represents AgNPs size distribution by intensity. The
591 summary statistics is based upon the intensity of light scattered of 6 different
592 samples derived from nanosilver dispersion.

593

594 Fig.3. Silver permeation profile in receiving phases of 8 cells exposed to AgNPs
595 (square) and of 6 cells exposed to Ag ions (diamonds) expressed as mean and
596 standard deviation.

597

598 Fig.4. Silver concentration in the mucosa of 7 cells exposed to AgNPs and 5 cells
599 exposed to Ag ions (median values, 25th and 75th quartiles, minimum and maximum
600 values, outsider value of $5.97 \mu\text{g}/\text{cm}^2$ in the mucosa exposed to AgNPs not showed
601 in the figure). $p = 0.61$ (Mann-Whitney test).

602

603 Fig.5. SEM images at increasing magnifications of the mucosal tissue exposed to
604 AgNPs with EDX microanalysis on the yellow spots (A: the entire sample –
605 bar=2mm; B: bar=500 μ m, C: bar=80 μ m, D: bar=70 μ m; E, F: bar=10 μ m).

606


607

Accepted Manuscript

607

FIGURES


608



609

610 Fig.1

611




612

613 Fig. 2

614

615




616

617 Fig.3


618

619




620

621 Fig.4




622

623 Fig.5 A




624

625 Fig.5 B




626

627 Fig.5 C




628

629 Fig.5 D



630

631 Fig.5 E



632

633 Fig.5 F

634

